You are here
May 18, 2020
In a JAMA Viewpoint, Dr. Collins and Johnson & Johnson’s Dr. Paul Stoffels describe the direction of the ACTIV public-private partnership to address the COVID-19 pandemic
The paper details the goals of the ACTIV partnership’s four working groups, which together aim to establish a collaborative framework to prioritize therapeutic and vaccine candidates and streamline human clinical trials. JAMA: Online: May 18, 2020.
This page last reviewed on May 18, 2020